JP2024522855A5 - - Google Patents

Info

Publication number
JP2024522855A5
JP2024522855A5 JP2023579138A JP2023579138A JP2024522855A5 JP 2024522855 A5 JP2024522855 A5 JP 2024522855A5 JP 2023579138 A JP2023579138 A JP 2023579138A JP 2023579138 A JP2023579138 A JP 2023579138A JP 2024522855 A5 JP2024522855 A5 JP 2024522855A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
arginine
polysorbate
histidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522855A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034747 external-priority patent/WO2022271962A1/en
Publication of JP2024522855A publication Critical patent/JP2024522855A/ja
Publication of JP2024522855A5 publication Critical patent/JP2024522855A5/ja
Pending legal-status Critical Current

Links

JP2023579138A 2021-06-23 2022-06-23 第ｖｉｉｉ因子キメラタンパク質の製剤およびその使用 Pending JP2024522855A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163214246P 2021-06-23 2021-06-23
US202163214245P 2021-06-23 2021-06-23
US63/214,246 2021-06-23
US63/214,245 2021-06-23
US202163214752P 2021-06-24 2021-06-24
US63/214,752 2021-06-24
US202163231909P 2021-08-11 2021-08-11
US63/231,909 2021-08-11
PCT/US2022/034747 WO2022271962A1 (en) 2021-06-23 2022-06-23 Formulations of factor viii chimeric proteins and uses thereof

Publications (2)

Publication Number Publication Date
JP2024522855A JP2024522855A (ja) 2024-06-21
JP2024522855A5 true JP2024522855A5 (enExample) 2025-06-30

Family

ID=82656587

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579138A Pending JP2024522855A (ja) 2021-06-23 2022-06-23 第ｖｉｉｉ因子キメラタンパク質の製剤およびその使用

Country Status (12)

Country Link
US (1) US20240287158A1 (enExample)
EP (1) EP4358938A1 (enExample)
JP (1) JP2024522855A (enExample)
KR (1) KR20240024949A (enExample)
AU (1) AU2022298798A1 (enExample)
BR (1) BR112023026782A2 (enExample)
CA (1) CA3220564A1 (enExample)
CO (1) CO2023017358A2 (enExample)
IL (1) IL309309A (enExample)
MX (1) MX2023015238A (enExample)
TW (1) TW202317178A (enExample)
WO (1) WO2022271962A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
EP4489771A2 (en) * 2022-03-08 2025-01-15 Bioverativ Therapeutics Inc. Methods of treating hemophilia a

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
EP2385825B1 (en) * 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
ES2770501T3 (es) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
AU2020298233A1 (en) * 2019-06-19 2022-01-20 Bioverativ Therapeutics Inc. Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density
WO2021032646A1 (en) * 2019-08-16 2021-02-25 Octapharma Ag Stabilizing buffer for factor viii and vwf
EP4489771A2 (en) * 2022-03-08 2025-01-15 Bioverativ Therapeutics Inc. Methods of treating hemophilia a

Similar Documents

Publication Publication Date Title
KR102843708B1 (ko) 이중특이적 항체 작제물을 포함하는 약제학적 조성물
AU2003234743B2 (en) Storage-stable, liquid fibrinogen formulation
ES2371038T3 (es) Péptidos y derivados peptídicos así como composiciones farmacéuticas que contienen los mismos.
JP2024099628A5 (enExample)
Girma et al. Limited proteolysis of human von Willebrand factor by Staphylococcus aureus V-8 protease: isolation and partial characterization of a platelet-binding domain
JP3701028B2 (ja) 高純度フォンビルブラント因子の入手方法
JP2020156520A5 (enExample)
JP2025148550A5 (enExample)
JP2024099682A5 (enExample)
US10357589B2 (en) One component fibrin glue comprising a polymerization inhibitor
ES2409888T3 (es) Purificación de un fibrinógeno
ES2333374T3 (es) Peptidos y derivados de peptidos, la produccion de los mismos asi como su uso para preparar una composicion farmaceutica terapeutica y/o preventivamente activa.
CN106414492A (zh) 包含因子viii和冯·维勒布兰德因子肽的制剂
JP2022151814A5 (enExample)
WO1990014103A1 (en) Polypeptide-antibody conjugate for inhibiting cell adhesion
AU2014237111B2 (en) Recombinant factor VIII formulations
WO2019219049A1 (zh) 改进的fviii融合蛋白及其应用
KR101080622B1 (ko) Ｖｉｉｉ:ｃ 인자-함유 폰 빌레브란트 인자의 농축물 및 이의 제조방법
CA3071930A1 (en) Hemopexin formulations
ES2420535T3 (es) Nuevo proceso para la purificación altamente selectiva de dos proteínas plasmáticas: factor de von willebrand (vwf) y fibronectina (fn).
JP2024538091A5 (enExample)
JP2022532445A (ja) 新規な中間体製造による持続型薬物結合体の製造方法
US20050004040A1 (en) Peptide having an affinity for gp120
CN103130872A (zh) 吸附剂、固相载体及精制方法
JPS6089433A (ja) 制癌作用物質複合体の製造法